Zacks Research Reduces Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Investment analysts at Zacks Research dropped their FY2024 EPS estimates for shares of Zimmer Biomet in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $7.98 per share for the year, down from their previous estimate of $7.99. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.38 EPS, FY2025 earnings at $8.51 EPS, Q3 2026 earnings at $2.21 EPS and FY2026 earnings at $9.18 EPS.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.65 EPS.

ZBH has been the subject of a number of other reports. BTIG Research cut their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 10th. TD Cowen lowered their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Wolfe Research assumed coverage on Zimmer Biomet in a report on Tuesday, September 10th. They set a “peer perform” rating for the company. Finally, Oppenheimer lowered their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $110.22 on Friday. The stock has a 50-day moving average price of $106.79 and a 200 day moving average price of $109.69. The stock has a market capitalization of $21.94 billion, a P/E ratio of 20.95, a P/E/G ratio of 1.99 and a beta of 1.02. Zimmer Biomet has a 12-month low of $101.47 and a 12-month high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of ZBH. BLB&B Advisors LLC increased its holdings in shares of Zimmer Biomet by 2.1% during the third quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 100 shares in the last quarter. FWG Holdings LLC grew its position in Zimmer Biomet by 2.9% during the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after purchasing an additional 101 shares during the last quarter. Financial Advocates Investment Management increased its stake in Zimmer Biomet by 3.5% during the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after purchasing an additional 103 shares in the last quarter. M&R Capital Management Inc. raised its holdings in shares of Zimmer Biomet by 14.1% in the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 105 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC lifted its stake in shares of Zimmer Biomet by 5.1% during the second quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock worth $238,000 after buying an additional 106 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.